3SBio Inc. (TRSBF)
| Market Cap | 6.90B +88.4% |
| Revenue (ttm) | 2.53B +94.3% |
| Net Income | 1.21B +305.8% |
| EPS | 0.49 +303.6% |
| Shares Out | n/a |
| PE Ratio | 5.69 |
| Forward PE | 16.20 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Average Volume | 709 |
| Open | 2.850 |
| Previous Close | 2.850 |
| Day's Range | 2.850 - 2.850 |
| 52-Week Range | 2.223 - 4.740 |
| Beta | 0.56 |
| RSI | 44.81 |
| Earnings Date | Aug 21, 2026 |
About 3SBio
3SBio Inc., an investment holding company, engages in the development, production, marketing, and sale of biopharmaceutical products in the People’s Republic of China, the United States, and internationally. The company offers TPIAO bio-pharmaceutical drug for the treatment of chemotherapy-induced thrombocytopenia, immune thrombocytopenia, pediatric ITP, and chronic liver disease-related thrombocytopenia. It also provides EPIAO for indications, such as the treatment of anemia associated with chronic kidney disease, chemotherapy-induced anemia, ... [Read more]
Financial Performance
In 2025, 3SBio's revenue was 17.70 billion, an increase of 94.29% compared to the previous year's 9.11 billion. Earnings were 8.48 billion, an increase of 305.78%.
Financial numbers in CNY Financial StatementsNews
Pfizer Signs $6B Deal with 3SBio for China-Based Cancer Drug
American drug giant Pfizer ($PFE) has entered into a $6 billion exclusive licensing deal with China’s 3SBio Inc. ($HK:1530) for its experimental cancer drug, SSGJ-707. According to the terms of…